No expert needed to hear Novartis patent appeal
An Indian court has decided on the composition of the board that will hear the appeal by Swiss drug maker Novartis against the rejection of its patent application for the blockbuster anti-cancer drug Glivec
On Monday the Chennai High Court accepted the governments proposal that the Intellectual Property Appellate Board (IPAB) hear the case without a technical member. This leaves only the chairman, Justice MHS Ansari and vice-chairman, ZS Negi.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.